What is mantle cell lymphoma?

Mantle cell lymphoma (MCL) is a rare type of blood cancer. It is a type of non-Hodgkin lymphoma.

It develops when blood cells called lymphocytes become abnormal. These blood cells normally help fight infection.

The abnormal lymphocytes usually build up in lymph nodes, but they can affect other parts of the body.

    Booklets and resources

    Symptoms of MCL

    Some people do not have any symptoms. The most common MCL symptom is a painless swelling or lump in the neck, armpit or at the top of the legs (groin). This is caused by lymphoma cells building up in the lymph nodes.

    Sometimes MCL can affect other areas of the body. Depending on the area, this can cause symptoms such as:

    • loss of appetite
    • diarrhoea
    • sickness (nausea)
    • a full feeling in the tummy (abdomen) – this is caused by an enlarged spleen
    • anaemia – this is caused by a low number of red blood cells in the blood.

    B symptoms

    MCL may also cause the following symptoms:

    • drenching night sweats
    • unexplained weight loss.

    These are called B symptoms. Along with staging and grading (below), B symptoms can help your cancer team understand:

    • how the lymphoma might develop
    • which treatments might help.

    Worried about symptoms?

    A change in how you feel or how your body works can be caused by conditions other than MCL. But always ask your GP to check any ongoing, new or unexplained symptoms.

    We are also here if you need someone to talk to. You can:

    Related pages

    Causes of MCL

    The causes of MCL are mostly unknown. It is most common in people over the age of 70. It is more common in men than women.

    Like other cancers, MCL is not infectious. You cannot spread it to other people.

    We have more general information about causes and risk factors of non-Hodgkin lymphoma.

    Diagnosis of mantle cell lymphoma

    If you have symptoms that worry you, you should begin by going to your GP. They may arrange for you to have blood tests or scans. If they think cancer may be causing your symptoms, they will refer you to a hospital for more tests and specialist advice and treatment.

    At the hospital, the doctor will ask about any symptoms, your general health and any illnesses you have had. They will also examine you.

    The most important test for diagnosing lymphoma is a biopsy. A biopsy means testing a small piece of tissue or a sample of cells from an area of the body affected. Sometimes MCL can be found with a blood test.

    Find out more about having a biopsy and other tests in our general lymphoma information.

    You may also have biopsies from other areas affected by symptoms. For example, if you have symptoms affecting your swallowing or stomach, you may have a test called an endoscopy to collect a biopsy sample.

    Waiting for test results

    Waiting for test results can be a difficult time. It may take up to 2 weeks for the results to be ready.

    You may find it helpful to talk to family members or a close friend. Your specialist nurse can also provide support.

    You can talk to one of our cancer support specialists for free on 0808 808 0000, 7 days a week, 8am to 8pm.

    Booklets and resources

    Staging of MCL

    Your test results give your cancer team more information about the lymphoma. This includes:

    The stage

    Staging describes how many areas of your body are affected by lymphoma and where these areas are.

    How the lymphoma cells are growing and are likely to behave

    Tests on the lymphoma cells can help your cancer team understand how quickly the cells are growing. Tests can also look for genetic changes or other features that are linked to faster growing MCL.

    Knowing more about the lymphoma helps your team plan the right treatment for you.

    Treatment for MCL

    A team of specialists will meet to discuss the best possible treatment for you. They are called a multidisciplinary team (MDT).

    After the MDT meeting, you will usually meet with your cancer doctor and specialist nurse. They will explain the different treatments and their side effects. They will also talk to you about things to consider when making treatment decisions.

    Your treatment for MCL may depend on:

    • whether you have symptoms that are causing problems
    • the stage of the lymphoma
    • the results of tests on the lymphoma cells
    • whether the lymphoma has become active again after previous treatment.

    You may need just one type of treatment or a combination of treatments.

    You may have some treatments as part of a clinical trial.

    Watch and wait

    Watch and wait means monitoring the lymphoma and checking for signs that you need to start treatment. It involves regular tests and appointments.

    Watch and wait may also be called active surveillance or active monitoring. It is a way of safely delaying treatment until it is needed.

    You might be offered watch and wait if MCL is not causing any symptoms.

    First line treatment

    The first treatment you have is called first line treatment. MCL is often treated with a combination of cancer drugs. The exact treatment you have might depend on your general health. Some treatments for MCL are more intensive than others.

    • Intensive cancer drug treatment with stem cell support

      Intensive treatment involves having:

      • cancer drugs to make all signs of MCL disappear – this is called remission
      • further high doses of cancer drugs to treat any remaining MCL
      • stem cell treatment to help you recover – this is called autologous stem cell treatment.

      The drugs you have will include an immunotherapy drug called rituximab and a high dose of a chemotherapy drug called cytarabine. You may have a targeted therapy drug as well.

    • Cancer drug treatment

      Intensive treatment can cause severe side effects. It is not suitable for everyone. If you are older than 65 or have other health conditions, your cancer team may plan a less intensive combination of cancer drugs for you.

      Treatment aims to make all signs of MCL disappear. This is called remission. Treatment also aims to reduce your risk of serious side effects. The drugs you have will usually include an immunotherapy called drug rituximab and chemotherapy. Drug combinations are often named after the initials of the drugs used. For example, R-CHOP includes: 

    • Low intensity cancer drug treatment

      People who are very unwell or frail may have low intensity treatment for MCL. The aims of this are to: 

      • treat the lymphoma as much as possible
      • reduce any symptoms of lymphoma.

      Your cancer team will explain which drugs might be right for you. For example, you may have a combination of an immunotherapy drug called rituximab and a chemotherapy drug such as bendamustine.

      Targeted therapy drugs are sometimes available as part of a clinical trial.

      Your team can arrange any help you need to manage symptoms or other health conditions. For example, some people may have radiotherapy to treat an area of lymphoma that is causing pain.

    • Radiotherapy

      Radiotherapy uses high-energy rays called radiation to treat cancer. It destroys cancer cells in the area where the radiotherapy is given.MCL is usually very sensitive to radiotherapy. You might have radiotherapy as your first treatment if the lymphoma only affects 1 or 2 groups of lymph nodes in the same part of the body. This is stage 1 or 2 lymphoma.

    Maintenance treatment

    If the lymphoma is in remission after the first line treatment, your cancer team may talk to you about having maintenance treatment. This means ongoing rituximab treatment every 8 weeks to help delay the lymphoma coming back. Your cancer team can tell you how long maintenance treatment might continue.

    Treating mantle cell lymphoma relapse

    First line treatment is often very effective. It may get rid of all signs of lymphoma for a time. But MCL usually comes back after treatment. This is called a recurrence or relapse.

    You can usually have more cancer drug treatment to help control it again. Your cancer team will explain which drugs are suitable for you. This may depend on the first line treatment you had.

    Treatments that may be used include:

    • a targeted therapy drug such as ibrutinib
    • rituximab and chemotherapy.

    A treatment called brexucabtagene autoleucel (Tecartus®) may be used to treat MCL that has come back. But it depends on the treatments you have already had. Brexucabtagene autoleucel is made from your own white blood cells. It is also called CAR T-cell therapy.

    After MCL treatment

    Follow-up after treatment for MCL

    You will have regular check-ups during and after your treatment for MCL. Your cancer doctor or specialist nurse will explain what to expect.

    Follow-up appointments are a good time for you to talk to your cancer doctor or specialist nurse about any concerns you have. Tell them as soon as possible if you have any problems or notice new symptoms between appointments. We have more information about follow-up care after treatment.

    Sometimes side effects may continue or develop months or years after treatment. These are called late effects. We have more information about late effects of lymphoma treatment.

    Wellbeing and recovery

    Looking after yourself can help speed up your recovery after MCL treatment. Even small lifestyle changes may improve your wellbeing and long term health.

    Even if you already have a healthy lifestyle, you may choose to make some positive changes after treatment. We have more information on leading a healthy lifestyle after treatment.

    Support for people with MCL

    People often have many different feelings during and after MCL treatment. If you have finished treatment, you may feel relieved it has ended but worried about what might happen in the future.

    It is important to know where to get support or information if you need it. People often need support even some time after MCL treatment. But sometimes it is difficult to know who to ask for help.

    You can:

    You may also find the HOPE programme helpful. The programme is a free 6 week self-management course designed to help you develop techniques and strategies when living with or after cancer. Topics include goal setting, fatigue management, and wellbeing.

    You can sign up for the online HOPE programme. Or to find out more about face to face programmes in your area, email ServiceOpsSupport@macmillan.org.uk

    Other organisations who offer information and support

    • Blood Cancer UK offers support and information to people affected by blood cancers, including lymphoma.
    • Lymphoma Action provides high quality information and support for people affected by lymphoma. It provides helpline services and a range of peer support including online support meetings, educational events and webinars. Its website includes TrialsLink, a database of lymphoma clinical trials.

    More information and advice

    We know cancer can affect you physically, emotionally and financially. We have information and advice about different ways cancer might impact you, such as help with:

    About our information

    This information has been written, revised and edited by Macmillan Cancer Support’s Cancer Information Development team. It has been reviewed by expert medical and health professionals and people living with cancer.

    • References

      Below is a sample of the sources used in our lymphoma information. If you would like more information about the sources we use, please contact us at informationproductionteam@macmillan.org.uk

       

      Cwynarski K, Marzolini MAV, Barrington SF, et al. The management of primary mediastinal B-cell lymphoma: a British Society for Haematology Good Practice Paper. Br J Haematol. 2019;185:402-9.

       

      Eyre TA, Bishton MJ, McCulloch R, et al. Diagnosis and management of mantle cell lymphoma: A British Society for Haematology Guideline. Br J Haematol. 2024;204(1):108–26.

       

      Ferreri AJM, Illerhaus G, Doorduijn K, et al., on behalf of the EHA and ESMO Guidelines Committees. Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35(6):491-507.

       

      Fox CP, Ahearne MJ, Pettengell R, et al. Guidelines for the management of mature T- and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma): a British Society for Haematology Guideline. Br J Haematol. 2022;196:507-22.

       

      Fox CP, Chaganti S, McIlroy G, et al. The management of newly diagnosed large B-cell lymphoma: A British Society for Haematology Guideline. Br J Haematol. 2024;204(4):1178–92.

       

      McNamara C, Montoto S, Eyre TA, et al. The investigation and management of follicular lymphoma. Br J Haematol. 2020;191:363-81.

       

      Pratt G, El-Sharkawi D, Kothari J, et al. Diagnosis and management of Waldenström macroglobulinaemia—A British Society for Haematology guideline. Br J Haematol. 2022;197:171–87.

       

      Walewska R, Eyre TA, Barrington S, et al. Guideline for the diagnosis and management of marginal zone lymphomas: A British Society of Haematology Guideline. Br J Haematol. 2024;204(1):86–107.

    Date reviewed

    Reviewed: 01 February 2025
    |
    Next review: 01 February 2028
    Trusted Information Creator - Patient Information Forum
    Trusted Information Creator - Patient Information Forum

    Our cancer information meets the PIF TICK quality mark.

    This means it is easy to use, up-to-date and based on the latest evidence. Learn more about how we produce our information.

    The language we use


    We want everyone affected by cancer to feel our information is written for them.


    We want our information to be as clear as possible. To do this, we try to:

    • use plain English
    • explain medical words
    • use short sentences
    • use illustrations to explain text
    • structure the information clearly
    • make sure important points are clear.

    We use gender-inclusive language and talk to our readers as ‘you’ so that everyone feels included. Where clinically necessary we use the terms ‘men’ and ‘women’ or ‘male’ and ‘female’. For example, we do so when talking about parts of the body or mentioning statistics or research about who is affected.


    You can read more about how we produce our information here.